[1]	WHO. Guidelines on clinical evaluation of vaccines: regulatory expectations[EB/OL].(2020-10-21)[2025-05-01]. https://www.who.int/publications/m/item/WHO-TRS-1004-web-annex-9. https://www.who.int/publications/m/item/WHO-TRS-1004-web-annex-9 Cited in this article [1]

[2]	WHO. Human papillomavirus vaccines:WHO position paper, December 2022[EB/OL].(2022-12-16) [2025-02-01]. https://www.who.int/publica-tions/i/item/who-wer9750-645-672. https://www.who.int/publica-tions/i/item/who-wer9750-645-672 Cited in this article [12]

[3]

Lehtinen M, Paavonen J, Wheeler CM, et al. Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial[J]. Lancet Oncol, 2012, 13(1):89-99. DOI:10.1016/S1470-2045(11)70286-8. Cited in this article [2]

[4]

Wheeler CM, Skinner SR, Del Rosario-Raymundo MR, et al. Efficacy,safety,and immunogenicity of the human papillomavirus 16/18 AS04-adjuvanted vaccine in women older than 25 years:7-year follow-up of the phase 3,double-blind,randomised controlled VIVIANE study[J]. Lancet Infect Dis, 2016, 16(10):1154-1168. DOI:10.1016/S1473-3099(16)30120-7. Cited in this article [2]

[5]

Puthanakit T, Huang LM, Chiu CH, et al. Randomized open trial comparing 2-dose regimens of the human papillomavirus 16/ 18 AS04-adjuvanted vaccine in girls aged 9-14 years versus a 3-dose regimen in women aged 15-25 years[J]. J Infect Dis, 2016, 214(4):525-536. DOI:10.1093/infdis/jiw036. Cited in this article [1]

[6]	Chen Q, Zhao H, Yao X, et al. Comparing immunogenicity of the Escherichia coli-produced bivalent human papillomavirus vaccine in females of different ages[J]. Vaccine, 2020, 38(39):6096-6102. DOI:10.1016/j.vaccine.2020.07.030. Cited in this article [2]

[7]	Hu YM, Guo M, Li CG, et al. Immunogenicity noninferiority study of 2 doses and 3 doses of an Escherichia coli-produced HPV bivalent vaccine in girls vs. 3 doses in young women[J]. Sci China Life Sci, 2020, 63(4):582-591. DOI:10.1007/s11427-019-9547-7. Cited in this article [2]

[8]	Li R, Li Y, Radley D, et al. Safety and immunogenicity of a vaccine targeting human papillomavirus types 6,11,16 and 18:A randomized,double-blind,placebo-controlled trial in Chinese males and females[J]. Vaccine, 2012, 30(28):4284-4291. DOI:10.1016/j.vaccine.2012.02.079. Cited in this article [2]

[9]	Dobson SR, McNeil S, Dionne M, et al. Immunogenicity of 2 doses of HPV vaccine in younger adolescents vs 3 doses in young women: a randomized clinical trial[J]. JAMA, 2013, 309(17):1793-1802. DOI:10.1001/jama.2013.1625. Cited in this article [1]

[10]	Ogilvie G, Sauvageau C, Dionne M, et al. Immunogenicity of 2 vs 3 doses of the quadrivalent human papillomavirus vaccine in girls aged 9 to 13 years after 60 months[J]. JAMA, 2017, 317(16):1687-1688. DOI:10.1001/jama.2017.1840. Cited in this article [1]

[11]	Lv H, Wang S, Liang Z, et al. Immunogenicity and safety of the 9-valent human papillomavirus vaccine in Chinese females 9-45 years of age: A phase 3 open-label study[J]. Vaccine, 2022, 40(23):3263-3271. DOI:10.1016/j.vaccine.2022.02.061. Cited in this article [3]

[12]	Iversen OE, Miranda MJ, Ulied A, et al. Immunogenicity of the 9-valent HPV vaccine using 2-dose regimens in girls and boys vs a 3-dose regimen in women[J]. JAMA, 2016, 316(22):2411-2421. DOI:10.1001/jama.2016.17615. Cited in this article [1]

[13]

Hu YM, Bi ZF, Zheng Y, et al. Immunogenicity and safety of an Escherichia coli-produced human papillomavirus (types 6/11/16/18/31/33/45/52/58) L1 virus-like-particle vaccine: a phase 2 double-blind, randomized, controlled trial[J]. Sci Bull (Beijing), 2023, 68(20):2448-2455. DOI:10.1016/j.scib.2023.09.020. Cited in this article [1]

[14]	Xie F, Du K, Li J, et al. Head-to-head immunogenicity comparison of one-dose Cecolin and Gardasil in Chinese girls aged 9-14 years: A randomized and open-label clinical trial[J]. Vaccine, 2025, 55:127015. DOI:10.1016/j.vaccine.2025.127015. Cited in this article [1]

[15]

Vesikari T, Brodszki N, van Damme P, et al. A randomized, double-blind, phaseⅢstudy of the immunogenicity and safety of a 9-valent human papillomavirus L1 virus-like particle vaccine (V503) versus gardasil® in 9-15-year-old girls[J]. Pediatr Infect Dis J, 2015, 34(9):992-998. DOI:10.1097/INF.0000000000000773. Cited in this article [1]

[16]	Joura EA, Giuliano AR, Iversen OE, et al. A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women[J]. New Engl J Med, 2015, 372(8):711-723. DOI:10.1056/NEJMoa1405044. Cited in this article [1]

[17]

Leung TF, Liu AP, Lim FS, et al. Comparative immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and 4vHPV vaccine administered according to two- or three-dose schedules in girls aged 9-14years:Results to month 36 from a randomized trial[J]. Vaccine, 2018, 36(1):98-106. DOI:10.1016/j.vaccine.2017.11.034. Cited in this article [1]

[18]

Mariz FC, Gray P, Bender N, et al. Sustainability of neutralising antibodies induced by bivalent or quadrivalent HPV vaccines and correlation with efficacy:a combined follow-up analysis of data from two randomised,double-blind, multicentre,phase 3 trials[J]. Lancet Infect Dis, 2021, 21(10):1458-1468. DOI:10.1016/S1473-3099(20)30873-2. Cited in this article [1]

[19]

Einstein MH, Takacs P, Chatterjee A, et al. Comparison of long-term immunogenicity and safety of human papillomavirus (HPV)-16/ 18 AS04-adjuvanted vaccine and HPV-6/11/16/18 vaccine in healthy women aged 18-45 years:end-of-study analysis of a PhaseⅢrandomized trial[J]. Hum Vaccin Immunother, 2014, 10(12):3435-3445. DOI:10.4161/hv.36121. Cited in this article [1]

[20]

Folschweiller N, Teixeira J, Joshi S, et al. Immunogenicity and safety of the AS04-HPV-16/18 and HPV-6/11/16/18 human papillomavirus vaccines in asymptomatic young women living with HIV aged 15-25 years:A phase Ⅳ randomized comparative study[J]. EClinicalMedicine, 2020, 23:100353. DOI:10.1016/j.eclinm.2020.100353. Cited in this article [1]

[21]

Zhu FC, Zhong GH, Huang WJ, et al. Head-to-head immunogenicity comparison of an Escherichia coli-produced 9-valent human papillomavirus vaccine and Gardasil 9 in women aged 18-26 years in China:a randomised blinded clinical trial[J]. Lancet Infect Dis, 2023, 23(11):1313-1322. DOI:10.1016/S1473-3099(23)00275-X. Cited in this article [1]

[22]	Herrero R, Wacholder S, Rodriguez AC, et al. Prevention of persistent human papillomavirus infection by an hpv16/18 vaccine:a community-based randomized clinical trial in guanacaste, costa rica[J]. Cancer Discov, 2011, 1(5):408-419. DOI:10.1158/2159-8290.CD-11-0131. Cited in this article [1]

[23]	Zhu FC, Hu SY, Hong Y, et al. Efficacy,immunogenicity and safety of the AS04-HPV-16/18 vaccine in Chinese women aged 18-25 years:End-of-study results from a phase Ⅱ/Ⅲrandomised, controlled trial[J]. Cancer Med, 2019, 8(14):6195-6211. DOI:10.1002/cam4.2399. Cited in this article [3]

[24]

Zhao FH, Wu T, Hu YM, et al. Efficacy,safety,and immunogenicity of an Escherichia coli-produced Human Papillomavirus (16 and 18) L1 virus-like-particle vaccine: end-of-study analysis of a phase 3, double-blind, randomised,controlled trial[J]. Lancet Infect Dis, 2022, 22(12):1756-1768. DOI:10.1016/S1473-3099(22)00435-2. Cited in this article [2]

[25]	Castellsagué X, Muñoz N, Pitisuttithum P, et al. End-of-study safety, immunogenicity, and efficacy of quadrivalent HPV (types 6,11,16,18) recombinant vaccine in adult women 24-45 years of age[J]. Brit J Cancer, 2011, 105(1):28-37. DOI:10.1038/bjc.2011.185. Cited in this article [3]

[26]

Wei LH, Xie X, Liu JH, et al. Efficacy of quadrivalent human papillomavirus vaccine against persistent infection and genital disease in Chinese women: A randomized, placebo-controlled trial with 78-month follow-up[J]. Vaccine, 2019, 37(27):3617-3624. DOI:10.1016/j.vaccine.2018.08.009. Cited in this article [2]

[27]	Huh WK, Joura EA, Giuliano AR, et al. Final efficacy,immunogenicity,and safety analyses of a nine-valent human papillomavirus vaccine in women aged 16-26 years: a randomised,double-blind trial[J]. Lancet, 2017, 390(10108):2143-2159. DOI:10.1016/S0140-6736(17)31821-4. Cited in this article [2]

[28]	Garland SM, Pitisuttithum P, Ngan HYS, et al.Efficacy,immunogenicity,and safety of a 9-valent human papillomavirus vaccine:subgroup analysis of participants from asian countries[J]. J Infect Dis, 2018, 218(1):95-108. DOI:10.1093/infdis/jiy133. Cited in this article [2]

[29]

Kavanagh K, Pollock KG, Cuschieri K, et al. Changes in the prevalence of human papillomavirus following a national bivalent human papillomavirus vaccination programme in Scotland:a 7-year cross-sectional study[J]. Lancet Infect Dis, 2017, 17(12):1293-1302. DOI:10.1016/S1473-3099(17)30468-1. Cited in this article [1]

[30]	Mesher D, Panwar K, Thomas SL, et al. The impact of the national HPV vaccination program in england using the bivalent HPV vaccine:surveillance of type-specific HPV in young females,2010-2016[J]. J Infect Dis, 2018, 218(6):911-921. DOI:10.1093/infdis/jiy249. Cited in this article [1]

[31]	Rebolj M, Pesola F, Mathews C, et al. The impact of catch-up bivalent human papillomavirus vaccination on cervical screening outcomes: an observational study from the English HPV primary screening pilot[J]. Br J Cancer, 2022, 127(2):278-287. DOI:10.1038/s41416-022-01791-w. Cited in this article [1]

[32]	Oliver SE, Unger ER, Lewis R, et al. Prevalence of human papillomavirus among females after vaccine introduction-national health and nutrition examination survey,united states,2003-2014[J]. J Infect Dis, 2017, 216(5):594-603. DOI:10.1093/infdis/jix244. Cited in this article [1]

[33]	Dillner J, Nygard M, Munk C, et al. Decline of HPV infections in Scandinavian cervical screening populations after introduction of HPV vaccination programs[J]. Vaccine, 2018, 36(26):3820-3829. DOI:10.1016/j.vaccine.2018.05.019. Cited in this article [2]

[34]	Drolet M, Bénard E, Pérez N, et al. Population-level impact and herd effects following the introduction of human papillomavirus vaccination programmes:updated systematic review and meta-analysis[J]. Lancet, 2019, 394(10197):497-509. DOI:10.1016/S0140-6736(19)30298-3. Cited in this article [4]

[35]	Hildesheim A, Wacholder S, Catteau G, et al. Efficacy of the HPV-16/18 vaccine:final according to protocol results from the blinded phase of the randomized Costa Rica HPV-16/18 vaccine trial[J]. Vaccine, 2014, 32(39):5087-5097. DOI:10.1016/j.vaccine.2014.06.038. Cited in this article [1]

[36]

Paavonen J, Naud P, Salmerón J, et al. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA):final analysis of a double-blind,randomised study in young women[J]. Lancet, 2009, 374(9686):301-314. DOI:10.1016/S0140-6736(09)61248-4. Cited in this article [1]

[37]	Garland SM, Hernandez-Avila M, Wheeler CM, et al. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases[J]. N Engl J Med, 2007, 356(19):1928-1943. DOI:10.1056/NEJMoa061760. Cited in this article [2]

[38]	FUTUREⅡStudy Group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions[J]. N Engl J Med, 2007, 356(19):1915-1927. DOI:10.1056/NEJMoa061741. Cited in this article [1]

[39]	Arbyn M, Xu L, Simoens C, et al. Prophylactic vaccination against human papillomaviruses to prevent cervical cancer and its precursors[J]. Cochrane Database Syst Rev, 2018,5:CD009069. DOI:10.1002/14651858.CD009069.pub3. Cited in this article [2]

[40]	Palmer T, Wallace L, Pollock KG, et al. Prevalence of cervical disease at age 20 after immunisation with bivalent HPV vaccine at age 12-13 in Scotland:retrospective population study[J]. BMJ, 2019,365:l1161. DOI:10.1136/bmj.l1161. Cited in this article [1]

[41]

Falcaro M, Castañon A, Ndlela B, et al. The effects of the national HPV vaccination programme in England,UK,on cervical cancer and grade 3 cervical intraepithelial neoplasia incidence:a register-based observational study[J]. Lancet, 2021, 398(10316):2084-2092. DOI:10.1016/S0140-6736(21)02178-4. Cited in this article [3]

[42]	Herweijer E, Sundstrom K, Ploner A, et al. Quadrivalent HPV vaccine effectiveness against high-grade cervical lesions by age at vaccination: A population-based study[J]. Int J Cancer, 2016, 138(12):2867-2874. DOI:10.1002/ijc.30035. Cited in this article [1]

[43]

Palmer TJ, Kavanagh K, Cuschieri K, et al. Invasive cervical cancer incidence following bivalent human papillomavirus vaccination:a population-based observational study of age at immunization,dose,and deprivation[J]. J Natl Cancer Inst, 2024, 116(6):857-865. DOI:10.1093/jnci/djad263. Cited in this article [1]

[44]	Lei J, Ploner A, Elfstrom KM, et al. HPV vaccination and the risk of invasive cervical cancer[J]. N Engl J Med, 2020, 383(14):1340-1348. DOI:10.1056/NEJMoa1917338. Cited in this article [2]

[45]	Kjaer SK, Dehlendorff C, Belmonte F, et al. Real-world effectiveness of human papillomavirus vaccination against cervical cancer[J]. J Natl Cancer Inst, 2021, 113(10):1329-1335. DOI:10.1093/jnci/djab080. Cited in this article [2]

[46]	张丽娜, 李克莉, 李燕, 等. 2017-2020年中国人乳头瘤病毒疫苗疑似预防接种异常反应监测[J]. 中国疫苗和免疫, 2023, 29(4):451-457. DOI:10.19914/j.CJVI.2023079. Cited in this article [1]

[47]	Saslow D, Andrews KS, Manassaram-Baptiste D, et al. Human papillomavirus vaccination 2020 guideline update: American Cancer Society guideline adaptation[J]. CA Cancer J Clin, 2020, 70(4):274-280. DOI:10.3322/caac.21616. Cited in this article [1]

[48]	Zhang J, Cheng K, Wang Z, et al. Prevalence and distribution of human papillomavirus genotypes in cervical intraepithelial neoplasia in China:a meta-analysis[J]. Arch Gynecol Obstet, 2020, 302(6):1329-1337. DOI:10.1007/s00404-020-05787-w. Cited in this article [1]

[49]	Moscicki AB. Impact of HPV infection in adolescent populations[J]. J Adolesc Health, 2005, 37(6 Suppl):S3-S9. DOI:10.1016/j.jadohealth.2005.09.011. Cited in this article [1]

[50]	Zhang J, Cheng K, Wang Z. Prevalence and distribution of human papillomavirus genotypes in cervical intraepithelial neoplasia in China:a meta-analysis[J]. Arch Gynecol Obstet, 2020, 302(6):1329-1337. DOI:10.1007/s00404-020-05787-w. Cited in this article [1]

[51]	Li Y, Zhao F, Wu D, et al. Prevalence of human papillomavirus and genotype distribution in chinese men: a systematic review and meta-analysis[J]. Cancer Med, 2025, 14(4):e70686. DOI:10.1002/cam4.70686. Cited in this article [1]

[52]	Giuliano AR, Palefsky JM, Goldstone S, et al. Efficacy of quadrivalent hpv vaccine against hpv infection and disease in males[J]. N Engl J Med, 2011, 364(5):401-411. DOI:10.1056/NEJMoa0909537. Cited in this article [2]

[53]	Ferris DG, Samakoses R, Block SL, et al. 4-Valent Human Papillomavirus (4vHPV) vaccine in preadolescents and adolescents after 10 years[J]. Pediatrics, 2017, 140(6):e20163947. DOI:10.1542/peds.2016-3947. Cited in this article [1]

[54]	Van Damme P, Meijer CJ, Kieninger D, et al. A phaseⅢclinical study to compare the immunogenicity and safety of the 9-valent and quadrivalent HPV vaccines in men[J]. Vaccine, 2016, 34(35):4205-4212. DOI:10.1016/j.vaccine.2016.06.056. Cited in this article [1]

[55]	Huang Y, Kang Y, Li Y, et al. HPV positivity status in males is related to the acquisition of HPV infection in females in heterosexual couples[J]. Eur J Clin Microbiol Infect Dis, 2024, 43(3):469-480. DOI:10.1007/s10096-023-04722-6. Cited in this article [1]

[56]	Man I, Georges D, Sankaranarayanan R, et al. Building resilient cervical cancer prevention through gender-neutral HPV vaccination[J]. Elife, 2023, 12:e85735. DOI:10.7554/eLife.85735. Cited in this article [1]

[57]	Barnabas RV, Brown ER, Onono MA, et al. Efficacy of single-dose HPV vaccination among young African women[J]. NEJM Evid, 2022, 1(5):EVIDoa2100056. DOI:10.1056/EVIDoa2100056. Cited in this article [1]

[58]

Basu P, Malvi SG, Joshi S, et al. Vaccine efficacy against persistent human papillomavirus (HPV) 16/18 infection at 10 years after one,two,and three doses of quadrivalent HPV vaccine in girls in India:a multicentre,prospective,cohort study[J]. Lancet Oncol, 2021, 22(11):1518-1529. DOI:10.1016/S1470-2045(21)00453-8. Cited in this article [1]

[59]	Kreimer AR, Herrero R, Sampson JN, et al. Evidence for single-dose protection by the bivalent HPV vaccine-review of the costa rica HPV vaccine trial and future research studies[J]. Vaccine, 2018, 36(32 Pt A):4774-4782. DOI:10.1016/j.vaccine.2017.12.078. Cited in this article [1]

[60]	Joshi S, Anantharaman D, Muwonge R, et al. Evaluation of immune response to single dose of quadrivalent HPV vaccine at 10-year post-vaccination[J]. Vaccine, 2023, 41(1):236-245. DOI:10.1016/j.vaccine.2022.11.044. Cited in this article [1]

[61]	Prem K, Choi YH, Bénard É, et al. Global impact and cost-effectiveness of one-dose versus two-dose human papillomavirus vaccination schedules:a comparative modelling analysis[J]. BMC Med, 2023, 21(1):313. DOI:10.1186/s12916-023-02988-3. Cited in this article [1]

[62]	文天萌, 由婷婷, 潘程浩, 等. 全球单剂次预防性人乳头瘤病毒疫苗接种研究进展及应用现状[J]. 中华肿瘤防治杂志, 2023, 30(20):1201-1207. DOI:10.16073/j.cnki.cjcpt.2023.20.01. Cited in this article [1]

[63]

Szarewski A, Poppe WA, Skinner SR, et al. Efficacy of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine in women aged 15-25 years with and without serological evidence of previous exposure to HPV-16/18[J]. Int J Cancer, 2012,131(1):106-116. DOI:10.1002/ijc.26362. Cited in this article [2]

[64]

Olsson SE, Kjaer SK, Sigurdsson K, et al. Evaluation of quadrivalent hpv 6/11/16/18 vaccine efficacy against cervical and anogenital disease in subjects with serological evidence of prior vaccine type hpv infection[J]. Hum Vaccin, 2009, 5(10):696-704. DOI:10.4161/hv.5.10.9515. Cited in this article [1]

[65]	Mac Eochagain C, Power R, Parker I, et al. HPV vaccination among seropositive,DNA negative cohorts:a systematic review & meta-analysis[J]. J Gynecol Oncol, 2022, 33(3):e24. DOI:10.3802/jgo.2022.33.e24. Cited in this article [1]

[66]	Joura EA, Kyrgiou M, Bosch FX, et al. Human papillomavirus vaccination:The ESGO-EFC position paper of the European society of gynaecologic oncology and the european federation for colposcopy[J]. Eur J Cancer, 2019, 116:21-26. DOI:10.1016/j.ejca.2019.04.032. Cited in this article [3]

[67]	Hu S, Xu X, Zhu F, et al. Efficacy of the AS04-adjuvanted HPV-16/18 vaccine in young Chinese women with oncogenic HPV infection at baseline:post-hoc analysis of a randomized controlled trial[J]. Hum Vaccin Immunother, 2021, 17(4):955-964. DOI:10.1080/21645515.2020.1829411. Cited in this article [1]

[68]

Wen TM, Xu XQ, Zhao XL, et al. Efficacy and immunogenicity of AS04-HPV-16/18 vaccine in females with existing cervical HR-HPV infection at first vaccination: A pooled analysis of four large clinical trials worldwide[J]. Int J Cancer, 2024, 154(12):2075-2089. DOI:10.1002/ijc.34882. Cited in this article [1]

[69]	Giuliano AR, Joura EA, Garland SM, et al. Nine-valent HPV vaccine efficacy against related diseases and definitive therapy: comparison with historic placebo population[J]. Gynecol Oncol, 2019, 154(1):110-117. DOI:10.1016/j.ygyno.2019.03.253. Cited in this article [1]

[70]	Human papillomavirus vaccination. ACOG Committee Opinion No.809[J]. Obstet Gynecol, 2020, 136(2):e15-e21. DOI:10.1097/AOG.0000000000004000. Cited in this article [4]

[71]

Kang WD, Choi HS, Kim SM. Is vaccination with quadrivalent hpv vaccine after loop electrosurgical excision procedure effective in preventing recurrence in patients with high-grade cervical intraepithelial neoplasia (cin2-3)[J]. Gynecol Oncol, 2013, 130(2):264-268. DOI:10.1016/j.ygyno.2013.04.050. Cited in this article [1]

[72]	Pieralli A, Bianchi C, Auzzi N, et al. Indication of prophylactic vaccines as a tool for secondary prevention in HPV-linked disease[J]. Arch Gynecol Obstet, 2018, 298(6):1205-1210. DOI:10.1007/s00404-018-4926-y. Cited in this article [1]

[73]

Chen M, Li C, Cui Q, et al. The efficacy of human papillomavirus prophylactic vaccination after conization in preventing cervical intraepithelial neoplasia recurrence:A prospective observational study in China[J]. Eur J Obstet Gynecol Reprod Biol, 2023, 286:10-15. DOI:10.1016/j.ejogrb.2023.04.014. Cited in this article [1]

[74]	Jentschke M, Kampers J, Becker J, et al. Prophylactic HPV vaccination after conization: A systematic review and meta-analysis[J]. Vaccine, 2020, 38(41):6402-6409.DOI:10.1016/j.vaccine.2020.07.055. Cited in this article [1]

[75]	Chen D, Juko-pecirep I, Hammer J, et al. Genome-wide association study of susceptibility loci for cervical cancer[J]. J Natl Cancer Inst, 2013, 105(9):624-633. DOI:10.1093/jnci/djt051. Cited in this article [1]

[76]	Ben W, Zhang GM, Huang YG, et al. MiR-27a-3p regulated the aggressive phenotypes of cervical cancer by targeting FBXW7[J]. Cancer Manag Res, 2020, 12:2925-2935. DOI:10.2147/CMAR.S234897. Cited in this article [1]

[77]	Shi Y, Li L, Hu Z, et al. A genome-wide association study identifies two new cervical cancer susceptibility loci at 4q12 and 17q12[J]. Nat Genet, 2013, 45(8):918-922. DOI:10.1038/ng.2687. Cited in this article [1]

[78]	中华医学会妇科肿瘤学分会, 中国优生科学协会阴道镜和宫颈病理学分会, 中华预防医学会肿瘤预防与控制专委会, 等. 预防性人乳头瘤病毒疫苗中国临床应用指南(2025版)[J]. 协和医学杂志, 2025, 16(2):350-360. DOI:10.12290/xhyxzz.2025-0246. Cited in this article [2]

[79]	Staadegaard L, Rönn MM, Soni N, et al. Immunogenicity, safety, and efficacy of the HPV vaccines among people living with HIV:A systematic review and meta-analysis[J]. E Clinical Medicine, 2022, 52:101585. DOI:10.1016/j.eclinm.2022.101585. Cited in this article [1]

[80]	McClymont E, Lee M, Raboud J, et al. The efficacy of the quadrivalent human papillomavirus vaccine in girls and women living human immunodeficiency virus[J]. Clin Infect Dis, 2019, 68(5):788-794. DOI:10.1093/cid/ciy575. Cited in this article [1]

[81]

Furer V, Rondaan C, Heijstek M, et al. Incidence and prevalence of vaccine preventable infections in adult patients with autoimmune inflammatory rheumatic diseases (AIIRD): a systemic literature review informing the 2019 update of the EULAR recommendations for vaccination in adult patients with AIIRD[J]. RMD Open, 2019, 5(2):e001041. DOI:10.1136/rmdopen-2019-001041. Cited in this article [2]

[82]

Rotstein Grein IH, Pinto NF, Lobo A, et al. Safety and immunogenicity of the quadrivalent human papillomavirus vaccine in patients with childhood systemic lupus erythematosus:a real-world interventional multi-centre study[J]. Lupus, 2020, 29(8):934-942. DOI:10.1177/0961203320928406. Cited in this article [1]

[83]	Grein IHR, Pinto NBF, Groot N, et al. Safety and immunogenicity of the quadrivalent human papillomavirus vaccine in patients with juvenile dermatomyositis: a real-world multicentre study[J]. Pediatr Rheumatol Online J, 2020, 18(1):87. DOI:10.1186/s12969-020-00479-w. Cited in this article [1]

[84]	Atiase Y, Effah K, Mawusi Wormenor C, et al. Prevalence of high-risk human papillomavirus infection among women with diabetes mellitus in Accra,Ghana[J]. BMC Womens Health, 2024, 24(1):260. DOI:10.1186/s12905-024-03078-z. Cited in this article [1]

[85]	Nelson DR, Neu AM, Abraham A, et al. Immunogenicity of human papillomavirus recombinant vaccine in children with CKD[J]. Clin J Am SocNephrol, 2016, 11(5): 776-784. DOI:10.2215/CJN.09690915. Cited in this article [1]

[86]	Hinten F, Meeuwis KA, van Rossum MM, et al. HPV-related (pre)malignancies of the female anogenital tract in renal transplant recipients[J]. Crit Rev Oncol Hematol, 2012, 84(2):161-180. DOI:10.1016/j.critrevonc.2012.02.008. Cited in this article [1]

[87]	Nailescu C, Nelson RD, Verghese PS, et al. Human papillomavirus vaccination in male and female adolescents before and after kidney transplantation:a pediatric nephrology research consortium study[J]. Front Pediatr, 2020, 8:46. DOI:10.3389/fped.2020.00046. Cited in this article [1]

[88]	Nailescu C, Ermel AC, Shew ML. Human papillomavirus-related cancer risk for solid organ transplant recipients during adult life and early prevention strategies during childhood and adolescence[J]. Pediatr Transplant, 2022, 26(7):e14341. DOI:10.1111/petr.14341. Cited in this article [1]

[89]	Kumar D, Unger ER, Panicker G, et al. Immunogenicity of quadrivalent human papillomavirus vaccine in organ transplant recipients[J]. Am J Transplant, 2013, 13(9):2411-2417. DOI:10.1111/ajt.12329. Cited in this article [1]

[90]

Chin-Hong PV, Reid GE. AST Infectious diseases community of practice.human papillomavirus infection in solid organ transplant recipients:guidelines from the american society of transplantation infectious diseases community of practice[J]. Clin Transplant, 2019, 33(9):e13590. DOI:10.1111/ctr.13590. Cited in this article [1]

[91]	Wacholder S, Chen BE, Wilcox A, et al. Risk of miscarriage with bivalent vaccine against human papillomavirus (HPV) types 16 and 18:pooled analysis of two randomised controlled trials[J]. BMJ, 2010,340:c712. DOI:10.1136/bmj.c712. Cited in this article [1]

[92]	Lipkind HS, Vazquez-Benitez G, Nordin JD, et al. Maternal and infant outcomes after human papillomavirus vaccination in the periconceptional period or during pregnancy[J]. Obstet Gynecol, 2017, 130(3):599-608. DOI:10.1097/AOG.0000000000002191. Cited in this article [1]

[93]	Faber MT, Duun-Henriksen AK, Dehlendorff C, et al. Adverse pregnancy outcomes and infant mortality after quadrivalent HPV vaccination during pregnancy[J]. Vaccine, 2019, 37(2):265-271. DOI:10.1016/j.vaccine.2018.11.030. Cited in this article [1]

[94]	Kharbanda EO, Vazquez-Benitez G, DeSilva MB, et al. Association of inadvertent 9-valent human papillomavirus vaccine in pregnancy with spontaneous abortion and adverse birth outcomes[J]. JAMA Netw Open, 2021, 4(4):e214340. DOI:10.1001/jamanetworkopen.2021.4340. Cited in this article [1]

[95]	Yan X, Li H, Song B, et al. Association of periconceptional or pregnancy exposure of HPV vaccination and adverse pregnancy outcomes:a systematic review and meta-analysis with trial sequential analysis[J]. Front Pharmacol, 2023, 14:1181919. DOI:10.3389/fphar.2023.1181919. Cited in this article [1]

[96]	Tan J, Xiong YQ, He Q, et al. Peri-conceptional or pregnancy exposure of HPV vaccination and the risk of spontaneous abortion:a systematic review and meta-analysis[J]. BMC Pregnancy Childbirth, 2019, 19(1):302. DOI:10.1186/s12884-019-2425-1. Cited in this article [1]

[97]	Oshman LD, Davis AM. Human papillomavirus vaccination for adults: updated recommendations of the Advisory Committee on Immunization Practices (ACIP)[J]. JAMA, 2020, 323(5):468-469. DOI:10.1001/jama.2019.18411. Cited in this article [2]

[98]

Wheeler CM, Castellsagué X, Garland SM, et al. Cross-protective efficacy of HPV-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types:4-year end-of-study analysis of the randomised, double-blind PATRICIA trial[J]. Lancet Oncol, 2012, 13(1):100-110. DOI:10.1016/S1470-2045(11)70287-X. Cited in this article [1]

[99]	Tsang SH, Sampson JN, Schussler J, et al. Durability of cross-protection by different schedules of the bivalent hpv vaccine:the cvt trial[J]. J Natl Cancer Inst, 2020, 112(10):1030-1037. DOI:10.1093/jnci/djaa010. Cited in this article [1]

[100]

Qiao YL, Wu T, Li RC, et al.Efficacy,safety,and immunogenicity of an Escherichia coli-produced bivalent human papillomavirus vaccine:An interim analysis of a randomized clinical trial[J]. J Natl Cancer Inst, 2020, 112(2):145-153. DOI:10.1093/jnci/djz074. Cited in this article [1]

[101]

Brown DR, Joura EA, Yen GP, et al. Systematic literature review of cross-protective effect of HPV vaccines based on data from randomized clinical trials and real-world evidence[J]. Vaccine, 2021, 39(16):2224-2236. DOI:10.1016/j.vaccine.2020.11.076. Cited in this article [1]

[102]

Artemchuk H, Eriksson T, Poljak M, et al. Long-term antibody response to human papillomavirus vaccines: up to 12 years of follow-up in the finnish maternity cohort[J]. J Infect Dis, 2019, 219(4):582-589. DOI:10.1093/infdis/jiy545. Cited in this article [1]

[103]

Schwarz TF, Huang LM, Valencia A, et al. A ten-year study of immunogenicity and safety of the AS04-HPV-16/18 vaccine in adolescent girls aged 10-14 years[J]. Hum Vaccin Immunother, 2019, 15(7-8):1970-1979. DOI:10.1080/21645515.2019.1625644. Cited in this article [1]

[104]

Porras C, Tsang SH, Herrero R, et al. Efficacy of the bivalent HPV vaccine against HPV 16/18-associated precancer: long-term follow-up results from the Costa Rica Vaccine Trial[J]. Lancet Oncol, 2020, 21(12):1643-1652. DOI:10.1016/S1470-2045(20)30524-6. Cited in this article [1]

[105]

Zhao F, Jastorff A, Hong Y, et al. Safety of AS04-HPV-16/18 vaccine in Chinese women aged 26 years and older and long-term protective effect in women vaccinated at age 18-25 years:A 10-year follow-up study[J]. Asia Pac J Clin Oncol, 2023, 19(4):458-467. DOI:10.1111/ajco.13833. Cited in this article [1]

[106]

Kjaer SK, Nygård M, Sundström K, et al. Final analysis of a 14-year long-term follow-up study of the effectiveness and immunogenicity of the quadrivalent human papillomavirus vaccine in women from four nordic countries[J]. E Clinical Medicine, 2020, 23:100401. DOI:10.1016/j.eclinm.2020.100401. Cited in this article [2]

[107]

Wen T, Xu X, Pan C, et al. The 13-year long-term follow-up on the effectiveness and immunogenicity of the quadrivalent human papillomavirus vaccine in Chinese females vaccinated at 20-45 years of age[J]. Hum Vacc immunother, 2023, 20(1):2412391. DOI:10.1080/21645515.2024.2412391. Cited in this article [1]

[108]

Restrepo J, Herrera T, Samakoses R, et al. Ten-year follow-up of 9-valent human papillomavirus vaccine:immunogenicity,effectiveness,and safety[J]. Pediatrics, 2023, 152(4):e2022060993. DOI:10.1542/peds.2022-060993. Cited in this article [1]

[109]

Kjaer SK, Falkenthal TEH, Sundström K, et al. Long-term effectiveness of the nine-valent human papillomavirus vaccine: Interim results after 12 years of follow-up in Scandinavian women[J]. Hum Vacc immunother, 2023, 20(1):2377903. DOI:10.1080/21645515.2024.2377903. Cited in this article [2]

[110]

Olsson SE, Villa LL, Costa RL, et al. Induction of immune memory following administration of a prophylactic quadrivalent human papillomavirus (HPV) types 6/11/16/18 L1 virus-like particle (VLP) vaccine[J]. Vaccine, 2007, 25(26):4931-4939. DOI:10.1016/j.vaccine.2007.03.049. Cited in this article [1]

[111]

Guevara A, Cabello R, Woelber L, et al. Antibody persistence and evidence of immune memory at 5years following administration of the 9-valent HPV vaccine. Vaccine, 2017, 35(37):5050-5057. DOI:10.1016/j.vaccine.2017.07.017. Cited in this article [1]

[112]

Luciani S, Bruni L, Agurto I, et al. HPV vaccine implementation and monitoring in Latin America. Implementación y monitoreo de la vacuna contra el VPH en América Latina[J]. Salud Publica Mex, 2018, 60(6):683-692. DOI:10.21149/9090. Cited in this article [1]

[113]

苏迎盈, 李维丽, 陈春林. 人乳头瘤病毒疫苗的研究进展和接种策略[J]. 中国实用妇科与产科杂志, 2024, 40(1):18-22. DOI:10.19538/j.fk2024010105. Cited in this article [1]

[114]

Garland SM, Cheung TH, McNeill S, et al. Safety and immunogenicity of a 9-valent HPV vaccine in females 12-26 years of age who previously received the quadrivalent HPV vaccine[J]. Vaccine, 2015, 33(48):6855-6864. DOI:10.1016/j.vaccine.2015.08.059. Cited in this article [1]

[115]

Stanley A.Plotkin, Walter A.Orenstein, Paul A. Offit. 疫苗(第6版)[M]. 罗凤基,杨晓明,王志军,时念民,主译. 北京: 人民卫生出版社,2017:139-140. Cited in this article [1]

[116]

CDC. Supplemental information and guidance for vaccination providers regarding use of 9-valent HPV[EB/OL]. (2016-11-29)[2025-05-10]. https://www.cdc.gov/hpv/downloads/9vhpv-guidance.pdf. https://www.cdc.gov/hpv/downloads/9vhpv-guidance.pdf Cited in this article [1]

[117]

Gilca V, Sauvageau C, Panicker G, et al. Immunogenicity and safety of a mixed vaccination schedule with one dose of nonavalent and one dose of bivalent HPV vaccine versus two doses of nonavalent vaccine - A randomized clinical trial[J]. Vaccine, 2018, 36(46):7017-7024. DOI:10.1016/j.vaccine.2018.09.057. Cited in this article [1]

[118]

Swedish KA, Factor SH, Goldstone SE. Prevention of recurrent high-grade anal neoplasia with quadrivalent human papillomavirus vaccination of men who have sex with men: a nonconcurrent cohort study[J]. Clin Infect Dis, 2012, 54(7):891-898. DOI:10.1093/cid/cir1036. Cited in this article [1]

[119]

Goldstone SE, Giuliano AR, Palefsky JM, et al. Efficacy, immunogenicity, and safety of a quadrivalent HPV vaccine in men: results of an open-label, long-term extension of a randomised, placebo-controlled, phase 3 trial[J]. Lancet Infect Dis. 2022; 22 (3): 413-425. Cited in this article [1]

[120]

Deshmukh AA, Chhatwal J, Chiao EY, et al. Long-Term outcomes of adding hpv vaccine to the anal intraepithelial neoplasia treatment regimen in hiv-positive men who have sex with men[J]. Clin Infect Dis, 2015, 61(10):1527-1535. DOI:10.1093/cid/civ628. Cited in this article [1]

[121]

Baandrup L, Maltesen T, Dehlendorff C, et al. Human papillomavirus vaccination and anal high-grade precancerous lesions and cancer-a real-world effectiveness study[J]. J Natl Cancer Inst, 2023, 116(2):283-287. DOI:10.1093/jnci/djad189. Cited in this article [1]

[122]

Mix JM, Saraiya M, Senkomago V, et al. High-Grade vulvar, vaginal, and anal precancers among u.s. adolescents and young adults after human papillomavirus vaccine introduction[J]. Am J Prev Med, 2022, 62(1):95-99. DOI:10.1016/j.amepre.2021.06.026. Cited in this article [1]

[123]

Dehlendorff C, Baandrup L, Kjaer SK. Real-world effectiveness of Human Papillomavirus vaccination against vulvovaginal high-grade precancerous lesions and cancers[J]. J Natl Cancer Inst, 2021, 113(7):869-874. DOI:10.1093/jnci/djaa209. Cited in this article [1]